An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients with Relapsed and/or Relapsed-Refractory Multiple Myeloma
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Melphalan flufenamide (Primary) ; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Oncopeptides
- 17 Jun 2021 Results (n=202) of pooled analysis from NCT01897714 and NCT02963493; assessing efficacy of Melflufen and dexamethasone in relapsed/refractory Multiple Myeloma, presented at the 26th Congress of the European Haematology Association
- 19 May 2021 According to an Oncopeptides media release, pooled analysis of the O-12-M1 and HORIZON studies are published online at ASCO.
- 19 May 2021 According to an Oncopeptides media release, pooled analysis of the O-12-M1 and HORIZON studies will be presented at the 2021 American Society of Clinical Oncology, ASCO